Key result
This review discusses evidence and provides recommendations on the prevention of VTE in cancer patients undergoing surgery, receiving medical therapy, or with central vein catheters.
Why the study?
Does prophylaxis with antithrombotic agents prevent VTE in cancer patients?
Does prophylaxis with antithrombotic agents prevent VTE in cancer patients?
This review discusses the evidence and provides recommendations for primary VTE prevention in surgical and medical cancer patients, balancing thrombotic risk against bleeding risk.
Recommendations for VTE prophylaxis in cancer patients balance thrombosis and bleeding risks; leaves open need for dedicated RCTs to refine strategies.
Patients with cancer who undergo surgery are at increased risk for venous thromboembolism (VTE). In addition, ‘medical’ cancer patients who receive chemotherapy, hormonal therapy, and/or radiation are also prone to develop VTE. Finally, cancer patients with central vein catheters (CVC) can develop CVC-associated thrombosis. Prophylaxis with antithrombotic agents can be problematic in cancer patients because they are also at increased risk for anticoagulant-induced bleeding. In this chapter we discuss the evidence and provide recommendations on the prevention of VTE in these three clinical settings.
No takes yet. Share an insight, caveat, or question.
Levine et al. (2003) conducted a review in Cancer and venous thromboembolism (VTE). Antithrombotic agents for VTE prophylaxis was evaluated. This review discusses evidence and provides recommendations on the prevention of VTE in cancer patients undergoing surgery, receiving medical therapy, or with central vein catheters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: